Tech Company Financing Transactions
Rampart Bioscience Funding Round
Rampart Bioscience secured a $85 million Series A funding round on 10/24/2023. Investors included Forbion Capital Partners, Healthcap Venture Capital and OrbiMed.
Transaction Overview
Company Name
Announced On
10/24/2023
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 West Clarendon Avenue 240
Phoenix, AZ 85013
USA
Phoenix, AZ 85013
USA
Phone
Undisclosed
Website
Email Address
Overview
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines -- including gene delivery, protein sciences and clinical translation -- to leap beyond the limitations of current gene therapies. Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Louis Breton
Chief Information Officer
Jeffrey Bartlett
Browse more venture capital transactions:
Prev: 10/24/2023: Innerworld venture capital transaction
Next: 10/24/2023: Blockaid venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs